Browsing Category News

Parents sue Pfizer over birth defects allegedly caused by Zoloft

A group of parents who claim their children suffered severe birth defects because of Zoloft has filed a lawsuit against the drug’s manufacturer. Mary and David Saville, Terry and Todd Cochran, Anita Kinslow, Wendell Houchens, Erica Woodley and Antwynette Golliday joined a lawsuit filed Dec. 2 in St. Clair County Circuit Court against Pfizer Inc. […]

Read More »

Category : News

Xoma shifts manufacturing to contractor, cuts 84 jobs

Xoma Corp. will cut 84 jobs — about one-third of its workforce — as the Berkeley-based drug developer shifts much of its manufacturing to a contractor. Xoma (NASDAQ: XOMA), which officially took “interim” off CEO John Varian’s title, said Thursday that it will eliminate 50 jobs immediately and cut the other 34 jobs by the […]

Read More »

Category : News

Bayer Yasmin Trial Is Postponed For Mediation

On the eve of the first trial in which Bayer faces accusations that it hid the risks of blood clots associated with its Yaz and Yasmin birth control pills, a federal judge has ordered that mediation should instead begin in hopes of reaching a settlement (here is the order). The move comes after a month […]

Read More »

Category : News

Merck Agrees To Disclose Clinical Trial Delays

Three months ago, Merck agreed to settle a derivative shareholder lawsuit over a clinical trial for the Vytorin cholesterol pill, which caused a tremendous controversy due to the handling of the trial data by the drugmaker and its former partner, Schering-Plough, which Merck subsequently acquired. You may recall the Enhance clinical trial was designed to […]

Read More »

Category : News

Size Matters… Even To FDA Reviewers

Now that we have your attention, we must confess this is not about penile matters. Rather, the issue involves generic tablets and the extent to which these differ in size from brand-name meds. To put it simply, generic tablets that are clearly much larger may pose safety and efficacy problems for patients, according to the […]

Read More »

Category : News

Synthes Accuses Stryker of Raiding California Sales Force, Taking Secrets

A unit of Synthes Inc. (SYST), the world’s largest maker of bone-related medical devices, accused Stryker Corp. (SYK) in a lawsuit of raiding its San Francisco sales force and using confidential information from former employees. Stryker seeks to obtain “an improper competitive advantage” in the industry for medical implants and instruments used in spinal surgery, […]

Read More »

Category : News

Novartis Suspends Production At A Key Plant

Late last month, Novartis quietly suspended production at a plant in Lincoln, Nebraska, where various over-the-counter and animal health meds are manufactured. The drugmaker is calling the move a voluntary step that is being taken for “compliance improvement activities” and to “expedite maintenance and improvements and continue to strengthen standards.” As a result, supplies of […]

Read More »

Category : News

Glaxo Is Fined For Vaccine Trials In Argentina

Following an investigation by the National Administration of Medicine, Food and Technology, the Argentine government has fined GlaxoSmithKline the equivalent of roughly $93,000 for its handling of vaccine trials several years ago in which 14 babies died. The probe found the drugmaker and two trial investigators failed to heed proper informed consent procedures, The Buenos […]

Read More »

Category : News

What Data? Alice In Clinical Trial Wonderland

A remarkable series of studies published this week in BMJ discloses various problems with clinical trials – or more specifically, publication of clinical trial data. As it turns out, there is a lot that goes missing. As the BMJ editorial laments: the articles “confirm the fact that a large proportion of evidence from human trials […]

Read More »

Category : News

FDA Issues Social Media Guidance… Well, Sort Of

Two years after first pondering social media guidelines, the FDA has finally issued a draft guidance that addresses, to a limited extent, the sort of communications that drugmakers can have with consumers, physicians and other parties in certain online settings. But the new guidance falls short of articulating any highly specific guidelines, although Twitter and […]

Read More »

Category : News

Subscribe Now

Featured Partner